Amos Elberg writes: I’m writing to let you know about a drug trial you may find interesting from a statistical perspective. As you may know, the relatively recent “orphan drug” laws allow (basically) companies that can prove an off-patent drug treats an otherwise untreatable illness, to obtain intellectual property protection for otherwise generic or dead […] The post Orpha